WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that several abstracts regarding regimens containing either ABT-493 or
paritaprevir, Enanta’s protease inhibitors being developed through its
collaboration with AbbVie, as well as an abstract regarding EDP-494,
Enanta’s wholly-owned pan-genotypic cyclophilin inhibitor for HCV
infection, have been accepted for presentation at The International
Liver Congress™ (ILC) 2016, in Barcelona, Spain, April 13-17.
New data will be presented from AbbVie’s investigational, pan-genotypic, once-daily, ribavirin-free regimen of ABT-493 and ABT-530 in patients with any of genotypes 1 through 6 chronic HCV infection, including data on treatment durations of as short as eight weeks in treatment-naïve, non-cirrhotic patients with genotype 1 (GT1), genotype 2 (GT2) or genotype 3 (GT3) chronic HCV infection. Additionally, abstracts being presented include real world data for regimens containing paritaprevir in patients with genotype 1 or genotype 4 chronic hepatitis C virus (HCV) infection, including patients with compensated cirrhosis (Child-Pugh A). Also being presented are in vitro data on EDP-494, Enanta’s alternative, host-targeted antiviral approach to HCV that targets the human host protein cyclophilin for hard to treat HCV resistance associated variants.
The following abstracts regarding ABT-493, paritaprevir, and EDP-494, will be presented during the International Liver Congress:
New data will be presented from AbbVie’s investigational, pan-genotypic, once-daily, ribavirin-free regimen of ABT-493 and ABT-530 in patients with any of genotypes 1 through 6 chronic HCV infection, including data on treatment durations of as short as eight weeks in treatment-naïve, non-cirrhotic patients with genotype 1 (GT1), genotype 2 (GT2) or genotype 3 (GT3) chronic HCV infection. Additionally, abstracts being presented include real world data for regimens containing paritaprevir in patients with genotype 1 or genotype 4 chronic hepatitis C virus (HCV) infection, including patients with compensated cirrhosis (Child-Pugh A). Also being presented are in vitro data on EDP-494, Enanta’s alternative, host-targeted antiviral approach to HCV that targets the human host protein cyclophilin for hard to treat HCV resistance associated variants.
The following abstracts regarding ABT-493, paritaprevir, and EDP-494, will be presented during the International Liver Congress:
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.